Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?

Landoas A, Perrier Q, Falque L, Saint-Raymond C, Briault A, Degano B, Chanoine S, Bedouch P · 2026 · Transplant Immunology · Atlas ID LANDOAS2026

What this study shows

In lung transplant recipients, later introduction of everolimus and a greater number of treatment interruptions were both risk factors for chronic lung allograft dysfunction; earlier, uninterrupted treatment was associated with lower CLAD risk (retrospective, single-centre; causality not established).

Abstract

ShowHide

Everolimus has been incorporated into the immunosuppressive management of lung transplant patients. Due to its anti-proliferative properties it is being studied in the context of chronic lung allograft dysfunction (CLAD). A retrospective single-centre observational study of lung transplant patients between January 2000 and August 2021 treated with everolimus during follow-up. The timing of everolimus introduction was identified as a risk factor for CLAD (OR 1.069, 95% CI 1.017-1.123), as was the number of everolimus discontinuations (OR 12.660, 95% CI 1.025-156.329).

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	3 - Human Observational
Model system	Human (single-centre retrospective observational)
Journal	Transplant Immunology
Year	2026
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1016/j.trim.2026.102436 · PMID 42648493

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	Everolimus
Target	mTOR
Model	Human
Effect	Early introduction and fewer interruptions associated with lower CLAD risk; lung function stability maintained

In the Atlas

Cite this paper

ShowHide

Landoas, A., Perrier, Q., Falque, L., Saint-Raymond, C., Briault, A., Degano, B., Chanoine, S., & Bedouch, P. (2026). Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102436

@article{LANDOAS2026,
  author       = {Landoas, A. and Perrier, Q. and Falque, L. and Saint-Raymond, C. and Briault, A. and Degano, B. and Chanoine, S. and Bedouch, P.},
  title        = {{Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?}},
  journal      = {Transplant Immunology},
  year         = {2026},
  doi          = {10.1016/j.trim.2026.102436},
  note         = {PMID: 42648493},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record LANDOAS2026) [Data set]. https://mtor-atlas.org/study/LANDOAS2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_LANDOAS2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record LANDOAS2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/LANDOAS2026/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?